World J Gastroenterol. 2009 May 28; 15(20): 2456-2462.
Published online 2009 May 28. doi: 10.3748/wjg.15.2456.
Enteropathic spondyloarthropathy: A common genetic background with inflammatory bowel disease?
Elisabetta Colombo, Anna Latiano, Orazio Palmieri, Fabrizio Bossa, Angelo Andriulli and Vito Annese.
Elisabetta Colombo, Fabrizio Bossa, Angelo Andriulli, Unit of Gastroenterology, Department of Medical Sciences, IRCCS-CSS Hospital, 1-71013 San Giovanni Rotondo, Italy
Anna Latiano, Orazio Palmieri, Angelo Andriulli, Vito Annese, Laboratory of Genetic Research, Department of Medical Sciences, IRCCS-CSS Hospital, 1-71013 San Giovanni Rotondo, Italy
Vito Annese, Unit of Digestive Endoscopy, Department of Medical Sciences, IRCCS-CSS Hospital, 1-71013 San Giovanni Rotondo, Italy
Author contributions: Colombo E, Latiano A, Andriulli A and Annese V wrote the paper; Palmieri O and Bossa F collected the literature, designed the tables, and listed the references.
Correspondence to: Vito Annese, MD, Unit of Digestive Endoscopy, Department of Medical Sciences, IRCCS-CSS Hospital, 1-71013 San Giovanni Rotondo, Italy. v.annese@operapadrepio.it
Telephone: +39-882-410784
Fax: +39-882-410784
Received February 2, 2009; Revised April 30, 2009; Accepted May 7, 2009;
Abstract
The association between spondyloarthropathy and inflammatory bowel disease (IBD) is largely established, although prevalence is variable because of different population selection and diagnostic methodologies. Most studies indicate that as many as 10%-15% of cases of IBD are complicated by ankylosing spondylitis (AS) or other forms of spondylarthritis (SpA). Of note, ileal inflammation resembling IBD has been reported in up to two thirds of cases of SpA, and it has been suggested that the presence of ileitis is associated with the chronicity of articular complications. Although this observation is of interest to unravel the pathophysiology of the disease, systematic screening of patients with SpA by ileocolonoscopy is not indicated in the absence of gut symptoms, as only a small proportion of patients with subclinical gut inflammation will develop overt IBD over time. The existence of familial clustering of both IBD and AS, the coexistence of both conditions in a patient, the evidence of an increased risk ratio among first- and second-degree relatives of affected AS or IBD patients and finally, the increased cross-risk ratios between AS and IBD, strongly suggest a shared genetic background. So far, however, IL23R is the only identified susceptibility gene shared by both IBD and AS. Although functional studies are still needed to better understand its pathogenic role, great effort is being spent therapeutically targeting this pathway that may prove effective for both disorders.
Keywords: Inflammatory bowel disease, Ulcerative colitis, Crohn’s disease, Ankylosing spondlitis, Sacroiliitis, Spondyloarthropathy
INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic relapsing inflammatory bowel diseases (IBDs) of unknown etiology that affect up to 1 in 250 of the adult population, with up to 25% of patients being diagnosed during childhood or adolescence[1]. Key features of UC include diffuse mucosal inflammation that extends proximally from the rectum. In CD, conversely, any site in the gastrointestinal tract may be affected with transmural inflammation, which is typically patchy and segmental[2]. Joint complications are the most common extra-intestinal manifestations of IBD, and were recognized as far back as the 1920s. Both axial and peripheral joint complications are recognized. This review mainly focuses on the so-called enteropathic spondyloarthropathy, and more specifically, on the possible pathogenic link which may lie in a common genetic background with IBD.
ANKYLOSING SPONDYLITIS (AS)
AS is a seronegative inflammatory arthropathy that affects the vertebral column, and is characterized by sacroiliitis and progressive ankylosis (fusion) of the vertebral facet joints. It is defined classically by the modified New York Criteria[3], which include: low back pain for more than 3 mo; relieved by exercise and not improved by rest; limited spinal movement in two planes; and decreased chest expansion. If any of these clinical features is present in association with bilateral grade 2-4 or unilateral grade 3-4 sacroiliitis, then a definitive diagnosis can be made. However, there is some overlap with the more general term of sponyloarthropathy (SpA), as defined by the European Study Group on Spondyloarthropathy[4]. This involves a combination of inflammatory low back pain and a number of other factors including associated conditions, such as IBD or enteric infection, post-dysenteric reactive arthritis, psoriatic arthritis, and post-urethritis arthritis. The prevalence of AS in the general population is 0.25%-1%[56], but it is increased in IBD patients to 1%-6%, depending on the study population and the method of investigation[78]. In a recent population-based study in Italy[9], the prevalence of AS was 0.37%, while IBD-associated arthritis accounted for 0.09%. However, the clinical spectrum might be broader than that so far defined. In a population-based inception cohort of IBD patients evaluated in Italy and Netherlands, 18% satisfied the European criteria for SpA, 3.1% satisfied the modified New York criteria for AS, however, 14.4% patients developed one or more SpA-related manifestations, without fulfilling any of the classification criteria[10].
The traditional method of radiological assessment is by plain radiology of the sacroiliac joints. Magnetic resonance imaging has demonstrated a higher sensitivity[59], although in the absence of symptoms, its significance is sometimes unclear. Idiopathic AS is more common in male subjects, with an M:F ratio of 3:1, whereas in IBD, the M:F ratio is closer to 1:1. The main lesion of AS is sacroiliitis and this is associated with inflammatory low back pain. The symptoms are characterized by an insidious onset over several months, morning stiffness, and exacerbation of pain by rest. The evolution of AS is usually independent of the bowel disease, and more often runs a more benign clinical course than idiopathic AS[11].
ISOLATED SACROILIITIS
Isolated sacroiliitis may occur in association with IBD, without evidence of progressive spinal disease. Although some patients complain of low back pain, in many cases, they may be asymptomatic, therefore, prevalence is dependent largely upon the investigation. Radiographic surveys suggest a prevalence of 18%[7], but higher prevalence is estimated by means of scintigraphy, with radioisotope uptake found in up to 52% of patients with CD and 42% with UC[12]. However, given the large degree of inter- and intra-observer error, and the lack of follow-up information about possible progression to AS, the significance of these findings is unclear. In the majority of patients, it seems a non-progressive condition. In clinical practice, diagnosis is usually made by plain abdominal radiography, but more often it is detected incidentally.
PERIPHERAL ARTHRITIS
Articular manifestations have been reported in association with IBD for many years, but only in the late 1950s was arthritis proven to be inflammatory, and quite distinct from classical rheumatoid arthritis (RA), to be seronegative. Articular manifestations occur in 5%-20% of IBD patients, and more recently, a new classification proposes two distinct clinical forms with specific genetic associations[13].
Type I peripheral arthropathy, defined as acute, self-limiting inflammation that affects fewer than five joint, and is associated with IBD relapse and the presence of other extra-intestinal manifestations. More often, large weight-bearing joints are affected, particularly knees, wrists and ankles. The median duration of illness is 5 wk, however, 10%-20% of patients will develop persistent symptoms. One third of patients will report one episode over time.
Type II arthritis is a symmetrical, seronegative, small-joint arthropathy, unrelated to disease activity. The onset may occur at any time during the course of IBD or before, and in CD, it is reported more commonly in colonic disease. It usually runs a more chronic course with a median duration of 3 years. The small joints of the hands are more commonly affected.
ROLE OF INTESTINAL INFLAMMATION
The role of intestinal inflammation and luminal factors in SpA is an area of debate. In a large series of ileocolonoscopy examinations with biopsies in patients with SpA[1415], inflammatory lesions were found in two thirds of patients, with a similar proportion in those with AS and RA. Moreover, the clinical course of articular disease was independent of the presence of gut inflammation, and a minority of patients (3.7%) developed overt IBD. In another study[16], 123 patients with SpA at initial endoscopy were reassessed clinically, and follow-up endoscopy performed in 49 patients. Articular remission rates were independent of initial gut inflammation and associated with endoscopic and histological remission. In addition, initial chronic gut inflammation implies a high risk of evolution of AS. Nevertheless, a potential confounding factor of these studies is that most patients are treated with non-steroidal anti-inflammatory drugs (NSAIDs) which may promote enteropathy that is hardly distinguishable from primary inflammatory lesions of the gut. Furthermore, in a follow-up study[17] of some patients still taking NSAIDs, no inflammatory gut lesions were found in those in clinical remission from articular symptoms, while in contrast, half of the patients with articular inflammation had persistent inflammatory gut lesions, and one quarter developed overt IBD. This suggests that intestinal inflammation is important in idiopathic as well IBD-associated AS, possibly by determining an increased antigenic load across the inflamed gut mucosa.
Post-enteric reactive arthritis is associated with Gram-negative enterobacteria such as Salmonella, Escherichia coli, Yersinia and Campylobacter; in these circumstances, bacterial antigens have been isolated in the affected joints. These conditions are clinically very similar to type I IBD arthritis, and it therefore seems likely that bacterial antigens may be important in the initiation of the inflammatory process. Furthermore, stronger support on the role of bacteria in initiating arthritis in the presence of gut inflammation has been gained from a study of HLA-B*27 transgenic animal models. These knock-out animals spontaneously develop colitis and axial and peripheral arthritis when reared under normal conditions[1819]. Interestingly, when they are kept in a germ-free environment, gut and joint inflammation is prevented[19]. Furthermore, different bacteria induce gut and joint inflammation with different efficiency, with Bacteroides vulgatus being the most efficient and E. coli is ineffective[20]. Thus, it appears likely that similarly to IBD, bacteria are important in the pathogenesis of SpA, with an interaction with the immune system. The link between bacteria, gut/joint inflammation and the immune response, might result from a (common) genetic predisposition.
GENETIC PREDISPOSITION TO SPONDYLOARTHROPATHY
Idiopathic AS is strongly associated with possession of HLA-B*27, with a 94% prevalence in northern European patients, compared with 10% of healthy controls[2122]. This association is considerably weaker in IBD-associated AS, ranging between 50% and 80% of patients[2325]. Conversely, 50% of HLA-B*27-positive IBD patients have AS, compared with 1%-10% of B*27-positive individuals in the general population. Putative mechanisms include B*27 presenting peptide from luminal bacteria, or self proteins causing an inflammatory response, or peptides being presented to the immune system by other antigens such as HLA-DR. Central to these theories is the concept of a triggering bacterial antigen, although evidence is lacking. Patients with isolated sacroiliitis are less likely to be HLA-B*27-positive, and HLA-B*27 seems to be a marker of progressive axial disease rather than sacroiliitis, but long-term studies are needed. Other genes in the HLA region have also been implicated including HLA-DR1, TAP and LMP, but none of these findings have been conclusive. Moreover, subsequent studies have demonstrated other HLA associations in IBD arthritis. The association with HLA-DRB1*0103 is solely with type I arthritis, which is also associated with HLA-B*27, whereas type II is associated with B*44 and MICA[1326] (Table 1).
Table 1
Table 1
HLA associations in IBD and IBD-associated arthropathy[11]
A number of studies have demonstrated a striking overlap within patients and family members with rheumatological, dermatological and gastrointestinal diseases. The susceptibility genes of these disorders appear to overlap with each other[27]. In a study that explored the prevalence of secondary disorders in 3287 AS individuals[28], the sub-group of patients with IBD-AS had higher prevalence of iritis (OR = 1.4) or psoriasis (OR = 1.9) than the controls. Moreover, patients with multiple disorders predicted the highest prevalence of co-existing disease (i.e. psoriasis, IBD, iritis, or AS) within family members. These data suggest that susceptibility factors are additive or have a synergistic effect on each other, thus pointing to a shared gene hypothesis.
GENETIC PREDISPOSITION TO IBD
IBD is widely believed to originate from a dysregulated immune response to luminal bacteria in a genetically susceptible host[2]. The inheritance model is non-Mendelian but complex-polygenic, with several genes involved together with environmental factors. Of the other environmental factors thought to have an impact on disease susceptibility, only smoking and appendectomy have a substantive evidence base[29]. Concordance data in twins (36% for CD and 16% for UC, 4% for both CD and UC for monozygotic and dizygotic twins, respectively) and multiplex IBD families (relative risk to first-degree relative of proband up to 35 for CD and 15 for UC) have provided strong epidemiological evidence for a genetic contribution to IBD susceptibility[30]. These observations have led to the development of genetic investigations with two broad strategies: one has investigated candidate genes, and the other has used hypothesis-free methods of genome-wide scanning.
Overall, candidate gene strategies have not proved to be particularly fruitful in IBD, but one success has been the identification of an association between the major histocompatibility complex (MHC) region and UC susceptibility, initially in Japanese subjects[31] and later in Europeans[32]. The DRB1*0103 allele has been implicated in both severe UC and extra-intestinal (mainly articular) manifestations of IBD. Subsequently, 11 genome-wide scans by non-parametric linkage analysis were performed in the 1990s, and several susceptibility loci were identified in approximately half of the chromosomes[33].
The NOD2 gene on chromosome 16q12 was the first susceptibility gene for CD to be identified successfully. It was detected by parallel strategies of positional cloning within a region of linkage and positional candidate gene investigation[3435], and the finding was subsequently widely replicated in Caucasian, but not in Asian populations. NOD2 encodes an intracellular receptor that is expressed predominantly in monocytes and Paneth cells[33]. This has been implicated in the innate immune response to muramyldipeptide (MDP), a component of peptidoglycan in bacterial cell walls. The CD-associated variants that are clustered in the C-terminal leucine-rich repeat part of the NOD2 protein significantly diminish responsiveness to MDP. On exposure to MDP, oligomerized NOD2 recruits RIP2 (the serine-threonine kinase RICK) and subsequently activates nuclear factor-?B transcription factor via NEMO ubiquitination and I?B degradation. This leads to production of cytokines and cryptidins/defensins, hence facilitating clearance of bacteria. In addition, there is evidence of cross-talk between NOD2 and toll-like receptor pathways. However, the precise mechanism by which NOD2 mutations lead to increased intestinal inflammation is unknown, but it may be that reduced ability to clear bacteria by innate immune mechanisms leads to dysregulation of adaptive immune pathways.
Following fine mapping of the IBD5 linkage region on chromosome 5q31, consistent evidence for association between CD and a haplotype of markers spanning 250 kb has been observed. More recently, the same locus has been associated also with UC[36]. However, because of the strong linkage disequilibrium (LD) across this region, it has been very difficult to identify the causal variant. Peltekova et al[37] have reported a two-locus risk haplotype in the region of the organic cation transporter (OCTN) genes and suggested that this accounts for the association. The two-locus haplotype comprises L503F (1672 C-T, missense substitution) and G207C (transversion) in the SLC22A4 (OCTN1) and SLC22A5 (OCTN2) genes, respectively. However, there remains significant debate as to whether these transcripts are truly implicated by the genetic evidence, and a number of other immunoactive candidates remain in the frame, including interferon regulatory factor 1 (IRF1) and a number of important cytokine genes (IL-3, IL-4, IL-5 and IL-13) located within the 250-kb risk haplotype.
Progress from the Human Genome Project and HapMap Project, combined with markedly decreasing genotyping costs, has made possible the performance of adequately powered genome-wide association studies (GWAs) in complex genetic disorders such as IBD. Several GWAs[38] and a meta-analysis[39] have already been performed in CD and more recently in UC[40] and pediatric IBD[41]. Genome scans have identified 11 susceptibility genes and loci and highlighted a number of new, previously unsuspected pathways as playing an important role in IBD pathogenesis, including the IL23 pathway in IBD overall and specific aspects of innate immunity (particularly the autophagy genes ATG16L1 and IRGM) in CD. As expected, a number of genes such as IL23r, IL12B, MHC, STAT3, IBD5, MST1, PTPN2, NKX2-3 seem to be shared in the predisposition to both UC and CD (Table 2).
Table 2
Table 2
Candidates genes and loci in CD and UC
COMMON GENETIC LINK BETWEEN IBD AND SPONDYLOARTHROPATHY
IBD and AS show familial clustering and may coexist in a patient. More intriguingly, healthy first-degree relatives of patients with AS (21%-60%) and CD (10%-54%) have increased permeability of the small intestine[4244]. These changes might be a consequence of subclinical intestinal inflammation, and conform to the profile of an additive trait in both conditions[4546]. Evidence from studies of twins and other first-degree relatives suggests that the genetic basis is somewhat stronger for IBD than for AS[4750].
In the pre-GWA era, studies investigating a possible common genetic background in IBD and articular involvement were concentrated mainly on MHC and NOD2. It has been recognized that genes in the HLA region have a greater role for modifying IBD phenotype than in determining overall disease susceptibility. Within UC clinical subgroups, the uncommon DRB1*0103 allele is associated with both extensive and severe disease, with an early need for surgery[51]. Interestingly, the same allele has also been associated with CD colitis, thus suggesting the molecular basis of a colonic IBD phenotype. Furthermore, type I pauciarticular large-joint arthritis is also associated with this allele and other class I alleles (B*27 and B*35) in LD. However, the low frequency of this allele suggests that this association is unlikely to be clinically useful in predicting disease course. In addition, an increased prevalence of extraintestinal manifestations has been reported previously in colonic IBD, increasing the possibility that the association between DRB1*0103 and articular manifestations may merely mirror the association with colonic disease. Finally, recent evidence from GWA scans has at least refined the signal to the 400-kb haplotype block that contains DRB1*0103, and shows that this locus is common to UC and the colonic (but not small bowel) sub-phenotype of CD[52].
Crane et al[53] have investigated the hypothesis that the three major variants of the NOD2 gene are involved in AS. A case-controlled study was performed in 229 AS, 197 IBD-associated AS (78 with CD and 119 with UC), and 229 ethnically matched healthy controls. The Gly908Arg variant was associated with UC-associated AS (OR = 4.6, 95% CI = 1.3-16, P = 0.016), with a similar non-significant trend in CD-associated AS (OR = 3.9, 95% CI = 0.8-18, P = 0.08). In contrast, no association was found between NOD2 variants and primary AS, or other variants with UC- or CD-associated AS. Moreover, carriage of the Pro268Ser variant was associated with greater disease activity. Similarly, in subsequent studies, variants of NOD2 do not appear to confer susceptibility to AS[54], but rather identify a subgroup of patient with CD-associated AS[55].
Recently, the Wellcome Trust Case Control Consortium and the Australo-Anglo-American Spondylitis Consortium have published the first association scan with 14 436 non-synonymous single nucleotide polymorphisms (SNPs) in 922 independent cases of AS, together with autoimmune thyroid disease, multiple sclerosis and breast cancer, against a common control dataset of 1500 healthy individuals[56]. The strongest association in AS was observed in the MHC region, centered around the HLA-B genes, but the association of P < 10-20 was observed across about 1.5 Mb, probably reflecting the strong effect of HLA-B27, even over distant SNPs with modest LD. To validate less strong signals obtained at the first scan, a further 471 independent AS cases and 625 new controls were genotyped with additional SNPs. In the combined data set, a strong association (P = 1.2 × 10-8 to 3.4 × 10-10) with SNPs of the ARTS1 gene (OR = 1.4) and IL23R gene (peak P value of 7.5 × 10-9 at the rs11209032 with an OR of 1.3) was found. The association with IL23R remained strong when considering individuals with AS not having IBD (n = 1066). These genes both represent excellent biological candidates, but more importantly, IL23R has been documented recently in CD and psoriasis[57], which suggests that this gene is a common susceptibility factor for the major seronegative diseases, at least partially explaining their co-occurrence. IL23R is a key factor in the regulation of a newly defined effector T-cell subset, TH17 cells[33]. They express high levels of the cytokine IL-17 in response to stimulation, in addition to IL-1, IL-6, tumor necrosis factor ?, IL-22 and IL-25. In animal models, blocking IL-23 reduces inflammation, which suggests that IL23R variants associated with disease are pro-inflammatory. No functional studies of IL23R variants are available to date, however a promising treatment of CD has been reported with anti-IL-12p40 antibodies, which block IL-12 and IL-23, as these cytokines share the p40 subunit[58].
A different perspective was employed in a study that explored the possible common genetic background of IBD and AS through a genealogical evaluation in Iceland[59]. Icelanders are relatively homogeneous with respect to the environment, cultural aspects and genetic factors; moreover, extensive genealogical records and diseases registries are available. By investigating the genealogical database and registry of subjects with AS (n = 205) and IBD (n = 1352), the risk ratios for relatives for each disease and the cross-risk ratios (AS vs IBD and vice versa) were estimated. First-, second- and third-degree relatives of patients with AS, had risk ratios of 94, 25 and 3.5, respectively, of developing AS (each P < 0.0005), while first-, second- and third-degree relatives of patients with IBD had risk ratios of 4.4, 2.2 and 1.4, respectively (each P < 0.0001). More intriguingly, the cross-risk ratio was 3.0 and 2.1 (P < 0.0001), respectively, in first- and second-degree relatives, with a comparable effect for UC and CD. This elevated cross-risk ratio between IBD and AS strongly suggests that there is a genetic component shared by these complex diseases, and should stimulate further molecular and functional studies.
CONCLUSION
The clinical association between spondyloarthropathy and IBD is well-established, with studies indicating that as many as 10%-15% of cases of IBD are complicated by AS or other forms of SpA[60]. Ileal inflammation that resembles IBD has been reported in up to two thirds of cases of SpA, and it has been suggested that the presence of ileitis is associated with the chronicity of articular complications. Moreover, evidence that there is familial clustering of IBD and AS, that both conditions may coexist in patients, that there is an increased risk ratio among first- and second-degree relatives of affected AS or IBD patients and finally, that there is an increased cross-risk ratios between AS and IBD, confirm the existence of a shared genetic predisposition. So far, IL23R is the only identified susceptibility gene shared by IBD and AS. Functional studies are still needed to better understand its functional role, but it is hoped that treatment that targets this pathway may prove effective in both disorders.
Footnotes
Peer reviewers: Nick P Thompson, MD, Department of Medicine, Freeman Hospital, Newcastle Upon Tyne, NE7 7DN, Unite Kingdom; Christian D Stone, MD, MPH, Director, Inflammatory Bowel Disease Program, Assistant Professor of Medicine, Division of Gastroenterology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8124, Saint Louis, MO 63110, United States
S- Editor Tian L L- Editor Kerr C E- Editor Ma WH
References
1.
Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429.
2.
Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
3.
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361-368.
4.
Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats A, Dijkmans B, Olivieri I, Pasero G. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34:1218-1227.
5.
Calin A. Ankylosing spondylitis. In:PJ Maddison, DA Isenberg, P Woo, DN Glass.,editors.Oxford textbook of rheumatology. Vol. 2. Oxford University Press: Oxford; 1998.pp.1058–1070.
6.
van der Linden S, van der Heijde DM. Clinical and epidemiologic aspects of ankylosing spondylitis and spondyloarthropathies. Curr Opin Rheumatol. 1996;8:269-274.
7.
Wright V, Watkinson G. Sacro-iliitis and ulcerative colitis. Br Med J. 1965;2:675-680.
8.
de Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol. 2000;27:2860-2865.
9.
De Angelis R, Salaffi F, Grassi W. Prevalence of spondylo-arthropathies in an Italian population sample: a regional community-based study. Scand J Rheumatol. 2007;36:14-21.
10.
Salvarani C, Vlachonikolis IG, van der Heijde DM, Fornaciari G, Macchioni P, Beltrami M, Olivieri I, Di Gennaro F, Politi P, Stockbrugger RW. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol. 2001;36:1307-1313.
11.
Orchard TR. Extraintestinal manifestations: skin, joint and mucocutaneous manifestations. In:J Satsangi, LR Sutherland.,editors.Inflammatory bowel disease. Elsevier Limited: Churchill Livingstone; 2003.pp.chapt. 43, 669-684.
12.
Agnew JE, Pocock DG, Jewell DP. Sacroiliac joint uptake ratios in inflammatory bowel disease: relationship to back pain and to activity of bowel disease. Br J Radiol. 1982;55:821-826.
13.
Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology. 2000;118:274-278.
14.
Mielants H, Veys EM, De Vos M, Cuvelier C, Goemaere S, De Clercq L, Schatteman L, Elewaut D. The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol. 1995;22:2266-2272.
15.
Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, Schatteman L, Elewaut D. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol. 1995;22:2273-2278.
16.
De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology. 1996;110:1696-1703.
17.
Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, Schatteman L, Gyselbrecht L, Elewaut D. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol. 1995;22:2279-2284.
18.
Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE Jr, Balish E, Taurog JD, Hammer RE, Wilson KH, Sartor RB. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest. 1996;98:945-953.
19.
Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL, Balish E, Hammer RE. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180:2359-2364.
20.
Rath H, Schulta M, Grenther W. Colitis, gastritis and antibacterial lymphocyte responses in HLA-B27 transgenic rats monoinoculated with Bacteroides vulgatus or Escherichia coli. Gastroenterology. 1997;112:A1068.
21.
Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet. 1973;1:904-907.
22.
Brown MA, Pile KD, Kennedy LG, Calin A, Darke C, Bell J, Wordsworth BP, Cornelis F. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis. 1996;55:268-270.
23.
Brewerton DA, Caffrey M, Nicholls A, Walters D, James DC. HL-A 27 and arthropathies associated with ulcerative colitis and psoriasis. Lancet. 1974;1:956-958.
24.
Dekker-Saeys BJ, Meuwissen SG, Van Den Berg-Loonen EM, De Haas WH, Meijers KA, Tytgat GN. Ankylosing spondylitis and inflammatory bowel disease. III. Clinical characteristics and results of histocompatibility typing (HLA B27) in 50 patients with both ankylosing spondylitis and inflammatory bowel disease. Ann Rheum Dis. 1978;37:36-41.
25.
Mallas EG, Mackintosh P, Asquith P, Cooke WT. Histoco-mpatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27). Gut. 1976;17:906-910.
26.
Orchard TR, Dhar A, Simmons JD, Vaughan R, Welsh KI, Jewell DP. MHC class I chain-like gene A (MICA) and its associations with inflammatory bowel disease and peripheral arthropathy. Clin Exp Immunol. 2001;126:437-440.
27.
Schreiber S, Rosenstiel P, Albrecht M, Hampe J, Krawczak M. Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet. 2005;6:376-388.
28.
Brophy S, Pavy S, Lewis P, Taylor G, Bradbury L, Robertson D, Lovell C, Calin A. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. J Rheumatol. 2001;28:2667-2673.
29.
Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-1517.
30.
Russell RK, Satsangi J. IBD: a family affair. Best Pract Res Clin Gastroenterol. 2004;18:525-539.
31.
Asakura H, Tsuchiya M, Aiso S, Watanabe M, Kobayashi K, Hibi T, Ando K, Takata H, Sekiguchi S. Association of the human lymphocyte-DR2 antigen with Japanese ulcerative colitis. Gastroenterology. 1982;82:413-418.
32.
Satsangi J, Welsh KI, Bunce M, Julier C, Farrant JM, Bell JI, Jewell DP. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet. 1996;347:1212-1217.
33.
Cho JH, Weaver CT. The genetics of inflammatory bowel disease. Gastroenterology. 2007;133:1327-1339.
34.
Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603.
35.
Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-606.
36.
Rioux JD, Daly MJ, Silverberg MS, Lindblad K, Steinhart H, Cohen Z, Delmonte T, Kocher K, Miller K, Guschwan S. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet. 2001;29:223-228.
37.
Peltekova VD, Wintle RF, Rubin LA, Amos CI, Huang Q, Gu X, Newman B, Van Oene M, Cescon D, Greenberg G. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet. 2004;36:471-475.
38.
Mathew CG. New links to the pathogenesis of Crohn disease provided by genome-wide association scans. Nat Rev Genet. 2008;9:9-14.
39.
Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40:955-962.
40.
Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, Domingues FS, Albrecht M, Nothnagel M, Ellinghaus D. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet. 2008;40:1319-1323.
41.
Kugathasan S, Baldassano RN, Bradfield JP, Sleiman PM, Imielinski M, Guthery SL, Cucchiara S, Kim CE, Frackelton EC, Annaiah K. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet. 2008;40:1211-1215.
42.
Vaile JH, Meddings JB, Yacyshyn BR, Russell AS, Maksymowych WP. Bowel permeability and CD45RO expression on circulating CD20+ B cells in patients with ankylosing spondylitis and their relatives. J Rheumatol. 1999;26:128-135.
43.
May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn’s disease?. Gastroenterology. 1993;104:1627-1632.
44.
Teahon K, Smethurst P, Levi AJ, Menzies IS, Bjarnason I. Intestinal permeability in patients with Crohn’s disease and their first degree relatives. Gut. 1992;33:320-323.
45.
Thjodleifsson B, Sigthorsson G, Cariglia N, Reynisdottir I, Gudbjartsson DF, Kristjansson K, Meddings JB, Gudnason V, Wandall JH, Andersen LP. Subclinical intestinal inflammation: an inherited abnormality in Crohn’s disease relatives?. Gastroenterology. 2003;124:1728-1737.
46.
Bjarnason I, Helgason KO, Geirsson AJ, Sigthorsson G, Reynisdottir I, Gudbjartsson D, Einarsdottir AS, Sherwood R, Kristjansson K, Kjartansson O. Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis. Gastroenterology. 2003;125:1598-1605.
47.
Lee JC, Lennard-Jones JE. Inflammatory bowel disease in 67 families each with three or more affected first-degree relatives. Gastroenterology. 1996;111:587-596.
48.
Peeters M, Nevens H, Baert F, Hiele M, de Meyer AM, Vlietinck R, Rutgeerts P. Familial aggregation in Crohn’s disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology. 1996;111:597-603.
49.
Orholm M, Binder V, Sorensen TI, Rasmussen LP, Kyvik KO. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol. 2000;35:1075-1081.
50.
Halfvarson J, Bodin L, Tysk C, Lindberg E, Jarnerot G. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology. 2003;124:1767-1773.
51.
Ahmad T, Tamboli CP, Jewell D, Colombel JF. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology. 2004;126:1533-1549.
52.
Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, Prescott NJ, Nimmo ER, Massey D, Berzuini C, Johnson C. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn’s disease. Nat Genet. 2008;40:710-712.
53.
Crane AM, Bradbury L, van Heel DA, McGovern DP, Brophy S, Rubin L, Siminovitch KA, Wordsworth BP, Calin A, Brown MA. Role of NOD2 variants in spondylarthritis. Arthritis Rheum. 2002;46:1629-1633.
54.
van der Paardt M, Crusius JB, de Koning MH, Murillo LS, van de Stadt RJ, Dijkmans BA, Pena AS, van der Horst-Bruinsma IE. CARD15 gene mutations are not associated with ankylosing spondylitis. Genes Immun. 2003;4:77-78.
55.
Laukens D, Peeters H, Marichal D, Vander Cruyssen B, Mielants H, Elewaut D, Demetter P, Cuvelier C, Van Den Berghe M, Rottiers P. CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn’s disease. Ann Rheum Dis. 2005;64:930-935.
56.
Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, Kwiatkowski DP, McCarthy MI, Ouwehand WH, Samani NJ. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007;39:1329-1337.
57.
Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, Ardlie KG, Civello D, Catanese JJ. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80:273-290.
58.
Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL. Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med. 2004;351:2069-2079.
59.
Thjodleifsson B, Geirsson AJ, Bjornsson S, Bjarnason I. A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genealogic study in Iceland. Arthritis Rheum. 2007;56:2633-2639.
60.
Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2006;20:451-471.